arrow
F

Fabian Hoti

iqvia, espoo, finland
H指数:26
被引数:2,723

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

与DPP-4i相比,在北欧2型糖尿病患者中使用恩格列净与全因死亡率,心力衰竭住院和终末期肾脏疾病的风险降低相关: EMPRISE (恩格列净比较有效性和安全性) 研究的结果

2024-10-120
OA
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
2023-08-313
OAAI